POPA Recon📢 Eli Lilly Q3 Earnings Preview: Can the Two Blockbuster Weight-Loss Drugs Continue to Push the Stock Higher? 👀
📢 Eli Lilly Q3 Earnings Preview: Can the Two Blockbuster Weight-Loss Drugs Continue to Push the Stock Higher? 👀 📅 Reporting before the market opens on Tuesday, Oct 29. Key focus areas include: whether the combined revenue from Mounjaro and Zepbound exceeds $15 billion; the sales ramp-up of the oral medication Orforglipron (referred to here as "Foundayo"); and whether the full-year guidance will be raised once again. 🟢 Consensus estimates point to revenue of approximately $22.5–$22.6 billion (up ~28% year-over-year) and non-GAAP EPS of roughly $5.70–$6.70 (impacted by IPR&D expenses). Mounja…
The excerpt is quoted from a public Telegram channel, which owns its text.